PIVKA-II NEW TUMOR MARKER for Liver Cancer Screening and Diagnostic (Hepatocellular carcinoma, HCC)
Liver cancer is a major cancer that causes death worldwide, including Thailand. In 2015, it was reported by the World
Health Organization (WHO) that there were 788,000 deaths caused by liver cancer which is one of the leading causes
second to lung cancer. Moreover, It is also reported by Ministry of Public Health in 2015 that cancer is the number
one cause of death in Thai people and the liver cancer is the number one cause of death
The risk factors of liver cancer
Hepatitis B, the most common cause of hepatitis in Thailand, fo unded in more than 6 million people. In addition,
hepatocellular carcinoma is caused by hepatitis C and other cirrhosis, such as alcohol, diabetic patients, patient
with high blood lipids, people who are obese or overweight, and people with non-alcoholic fatty liver disease.
The symptoms of liver cancer include abdominal discomfort, anorexia, upper right abdominal pain, yellow skin and
yellow eyes (jaundices), and itching. However, at the early stage of liver cancer, symptoms are usually not shown.
Early detection of liver cancer will enable patients to respond to effective treatment and more likely to be cured.
Therefore, liver cancer screening can assist in the early detection.
Des-gamma-Carboxy Prothrombin is a type of protein that is crea ted when the body is deficient in vitamin K,
resulting in the formation of prothrombin (an erectile dysfunct ion agent). The abnormalities are called PIVK A-II.
Hepatocellular carcinoma (HCC) causes abnormalities and causes vitamin K deficiency, resulting in the formation of
PIVKA-II and released in the blood circulation.
Studies have shown that PIVKA-II is more sensitive and specific
to AFP in the diagnosis of liver cancer, and that using PIVKA-II
and AFP together will increase sensitivity and accuracy.
PIVKA-II Sensitivity 77% Specificity 82%
AFP Sensitivity 61% Specificity 50%
PIVKA-II + AFP Sensitivity 84% Specificity 83%
The test should be under the discretion of a physician. | The mentioned test is performed by the laboratory with ISO 15189 certification and lab accreditation.
*This operation schedule is for the test performed at N Health head quarter, Bangkok.
**Above turnaround time does not include logistic time. For BDMS network hospitals, please contact N Health laboratory located at your hospitals.
1 http://www.thasl.org/th/academic.php แนวทางการดูแลผู้ป่วยมะเร็งตับในประเทศไทย ปี พ.ศ. 2558 สมาคมโรคตับแห่งประเทศไทย